Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection

This study has been completed.
Astellas Pharma Canada, Inc.
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: April 20, 2009
Last updated: September 17, 2014
Last verified: September 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2006
  Primary Completion Date: July 2004 (Final data collection date for primary outcome measure)